LGC

Join us at #AMP2024 in Vancouver, November 19–23, at Booth 1427. We’ll present a workshop on Improving Liquid Biopsy Concordance and showcase key posters on novel, benchmark reference materials. Access valuable resources, including acclaimed posters from last year! Schedule time with our experts to discuss innovative solutions: https://hubs.ly/Q02VVtqS0 #AMP2024 #LGCClinicalDiagnostics #SeraCare

We're heading to CPHI & PMEC India next month! Visit us at stand 2.D36 to explore our comprehensive range of pharmaceutical reference standards🔗https://okt.to/SXkZeO Our APAC Channel Manager Raghvendra Sharma will be there to connect with you from Nov 26 to 28. Swing by our stand and discuss your analytical needs. We can't wait to meet you there! #CPHIIndia #PharmaIndustry #ReferenceStandards #APIs #ImpurityStandards #QualityControl

Axolabs is headed to Washington, DC! 🌎 We look forward to attending the DIA/FDA Oligonucleotide-Based Therapeutics Conference, from October 28-30, 2024! Axolabs will join industry leaders and sharing insights on CMC guidance updates, delivery methods, safety assessments, and more regulatory topics in oligonucleotide-based therapeutics. Send us a DM if you would like to connect in DC! #Oligonucleotides #Axolabs #RNATherapeutics # DIAFDAConference

🎗Mutations in the BRCA1 and BRCA2 genes are responsible for a large number of hereditary breast and ovarian cancer cases. A specific type of mutation, called large genomic rearrangements, involves the loss or gain of entire sections of the gene. These mutations account for up to 27% of all BRCA mutations but can be missed by common testing methods. Because of the challenges in detecting these mutations, there is a need for a more thorough BRCA1/2 testing approach, which includes using special reference materials to help identify these changes. Accurate detection is essential, as clinical studies have shown that patients with BRCA mutations respond well to certain treatments. Reference material from SeraCare is designed for next-generation sequencing platforms, and supports the accurate detection of challenging mutations and enhances the clinical utility of tests that inform treatment decisions, including the use of poly-ADP ribose polymerase (PARP) inhibitors. Sign up at the link to for more information: https://ow.ly/wA5x50TQSuc #ScienceforaSaferWorld #BRCA #GenomicTesting #BreastCancerAwarenessMonth

🎗Advancing Cancer Diagnostics: Global Collaboration in PIK3CA Mutation Testing In partnership with the National Institute of Metrology (NIM) China, the UK National Measurement Laboratory (NML) at LGC is validating reference methods for three common PIK3CA mutation variants. The PIK3CA gene is frequently mutated in breast cancer, contributing to uncontrolled cell growth and tumour formation. Due to its activity, it is a target for treatments, such as newly approved Piqray (alpelisib). To ensure treatments are appropriate for patients, accurate genetic testing is crucial. The collaboration includes a six-month secondment of NIM researcher, Dr. Chunyan Niu, at NML, pictured below, focusing on validating methods for trueness and specificity. These efforts will enhance the quality and comparability of cancer diagnostic tests, supporting the development of reliable reference methods that can improve genomic method validation globally. This work is part of the EURAMET - The European Association of National Metrology Institutes project, GenomeMET, which is driving advancements in cancer diagnostics through collaboration. #ScienceforaSaferWorld #CancerDiagnostics #GenomicMedicine #Metrology #BreastCancer #MeasurementMatters

Are you interested in genomics innovations and how we can involve people from all backgrounds to scale potential benefits? Then take a listen to the latest podcast from Sano Genetics who interview Mark Taylor, Head of Strategic Partnerships about the next stage of precision medicine. #ScienceforaSaferWorld #Genomics #GrantManagementGroup NIHR (National Institute for Health and Care Research)

🎗️ Supporting Breast Cancer Research and Diagnostics with LGC Standards This #BreastCancerAwarenessMonth, we reocgnise the essential role reference materials play in advancing breast cancer diagnostics and research, such as those from LGC Standards. From BRCA1/2 testing to assay performance, high-quality standards support laboratories worldwide in delivering accurate, reliable results. Find out how LGC Standards and reference materials contribute to the fight against breast cancer at this link: https://ow.ly/ZNYV50TNpFv #ScienceforaSaferWorld #CancerDiagnostics #CancerResearch

📢#SaveTheDate Join LGC AXIO Proficiency Testing’s upcoming webinar, 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝗼𝗳 𝘆𝗼𝘂𝗿 𝗣𝗧 𝗱𝗮𝘁𝗮 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗻𝗲𝘄 𝗗𝗮𝘁𝗮 𝗗𝗮𝘀𝗵𝗯𝗼𝗮𝗿𝗱 on November 20: https://okt.to/PFa3rQ. Our Head of Data & Reporting, Richard Loftus, and our Head of Technical Operations, Matthew Whetton, will be demonstrating the power of the recently launched PORTAL Data Dashboard. PORTAL is LGC AXIO’s best-in-class reporting platform, allowing users to upload and analyse their results submissions in a variety of ways, with full reports delivered in an industry-beating 5.8 working days. Whether you’re already a PORTAL user or have yet to try it, this webinar will explain: ✔️The benefits of PT participation with LGC AXIO PT. ✔️How to ensure you’re using PORTAL to its maximum capacity. ✔️How to review your PT performance effectively, all using the new Data Dashboard. There will also be a Q&A session at the end. Don't miss out and register for the webinar now! 📅November 20, 2024 ⏲️14:00 GMT #Webinar #PORTAL #ProficiencyTesting #DrivingQualityTogether

🎗BRCA1 and BRCA2 tumour suppressor genes play a critical role in limiting DNA damage. Mutations in these genes significantly increase the risk of breast cancer, among others. Accurate detection of BRCA variants is essential for guiding cancer treatment strategies and for those carrying inherited mutations to explore preventive measures. Download SeraCare's scientific poster to discover how newly developed reference materials support BRCA1 and BRCA2 genetic testing, offering laboratories and assay developers the tools to optimise NGS-based detection of pathogenic variants. https://ow.ly/Ngfk50TAhOI #ScienceforaSaferWorld #BreastCancerAwarenessMonth #BRCAResearch #GeneticTesting #CancerDetection #AssayDevelopment

🏅INFORMED Sport Certification Milestone for Holland & Barrett Holland & Barrett now holds the record as the company to certify the most products with Informed Sport at the beginning of a partnership. With more than 60 product variances through their new and improved range of Precision Engineered Sports nutrition, Holland & Barrett has also become one of the largest ranges in the UK to be certified by Informed Sports. Informed Sport's rigorous programme means that every single batch has been tested and has undergone a robust certification process. Jamie Cooper, Head of Commercial Trading for Sports at Holland & Barrett, said: “Informed Sports certification is a game changer for our new and improved Precision Engineered Range, making it the ultimate sports nutrition for people who demand results, whilst still offering great value.” Read more here: https://ow.ly/uW5j50TMMHw #ScienceforaSaferWorld